NKT-2 Activator Composition Suppresses Type I NKT Cell Damage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for alcoholic liver disease (ALD) are inadequate due to the complex immunological and anatomical uniqueness of the liver, with a lack of effective methods to halt the progression of inflammation and tissue damage caused by excessive alcohol consumption.
Innovation Solution
Administering a composition comprising an NKT-2 activator, such as miltefosine, and sulfatide to activate type II NKT cells, which inhibits the activation of type I NKT cells, thereby reducing inflammation and tissue damage in conditions like ALD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic approaches are used for alcoholic liver disease, then treatment is provided, but the progression of inflammation and tissue damage is not effectively halted
Solution Approach 1:
The patent uses type II NKT cells as intermediary agents to mediate the therapeutic effect. These cells are activated by the composition (containing sulfatide and/or NKT-2 activator) and then exert their protective function by suppressing type I NKT cell-mediated damage, thereby indirectly protecting liver tissue from inflammation and damage caused by alcohol consumption
Solution Approach 2:
The treatment works by activating type II NKT cells in advance to suppress the harmful effects of type I NKT cells before they can cause significant tissue damage. The composition is administered to pre-activate protective immune cells, creating a preliminary anti-action against the harmful inflammatory response that would otherwise be triggered by alcohol-induced stress
2Reliability
If type I NKT cells are activated, then immune response is enhanced, but type I NKT cell-mediated tissue damage occurs
Solution Approach 1:
The patent employs type II NKT cells as a counterbalancing force against type I NKT cells. By activating type II NKT cells through the composition, they exert a suppressive effect on type I NKT cell activity, creating an immune balance where the protective response counterweights the harmful tissue-damaging response
Solution Approach 2:
Type II NKT cells serve as intermediary regulators that modulate the activity of type I NKT cells. Rather than directly blocking type I NKT cell activation, the activated type II NKT cells intervene to suppress their harmful effects, providing a nuanced immune regulation mechanism
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
In accordance with some embodiments herein, methods and compositions for prevention and treatment of inflammatory conditions are provided. In some embodiments, compositions comprising NKT-2 activators, for example miltefosine are provided. In some embodiments, the compositions further comprise sulfatide and/or a RAR agonist. In some embodiments, the compositions comprise activators of Type II NKT cells, and/or inhibitors of Type I NKT cells.